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Abstract 
Background: The diagnosis of malaria during pregnancy is complicated by placental sequestration, asymptomatic 
infection, and low‑density peripheral parasitaemia. Where intermittent preventive treatment (IPT) with sulfadoxine‑
pyrimethamine is threatened by drug resistance, or is inappropriate due to low transmission, intermittent screening 
and treatment (ISTp) with rapid diagnostic tests for malaria (RDT) could be a valuable alternative. Therefore, the accu‑
racy of RDTs to detect peripheral and placental infection was assessed in a declining transmission setting in Papua 
New Guinea (PNG).
Methods: The performance of a combination RDT detecting histidine‑rich protein‑2 (HRP‑2) and Plasmodium lactate 
dehydrogenase (pLDH), and light microscopy (LM), to diagnose peripheral Plasmodium falciparum and Plasmo-
dium vivax infections during pregnancy, were assessed using quantitative real‑time PCR (qPCR) as the reference 
standard. Participants in a malaria prevention trial in PNG with a haemoglobin ≤90 g/L, or symptoms suggestive of 
malaria, were tested. Ability of RDT and LM to detect active placental infection on histology was evaluated in some 
participants.
Results: Among 876 women, 1162 RDTs were undertaken (anaemia: 854 [73.5 %], suspected malaria: 308 [26.5 %]). 
qPCR detected peripheral infection during 190 RDT episodes (165 P. falciparum, 19 P. vivax, 6 mixed infections). Overall, 
RDT detected peripheral P. falciparum infection with 45.6 % sensitivity (95 % CI 38.0–53.4), a specificity of 96.4 % 
(95.0–97.4), a positive predictive value of 68.4 % (59.1–76.8), and a negative predictive value of 91.1 % (89.2–92.8). RDT 
performance to detect P. falciparum was inferior to LM, more so amongst anaemic women (18.6 vs 45.3 % sensitivity, 
Liddell’s exact test, P < 0.001) compared to symptomatic women (72.9 vs 82.4 % sensitivity, P = 0.077). RDT and LM 
missed 88.0 % (22/25) and 76.0 % (19/25) of P. vivax infections, respectively. In a subset of women tested at delivery 
and who had placental histology (n = 158) active placental infection was present in 19.6 %: all three peripheral blood 
infection detection methods (RDT, LM, qPCR) missed >50 % of these infections.
Conclusions: In PNG, HRP‑2/pLDH RDTs may be useful to diagnose peripheral P. falciparum infections in symp‑
tomatic pregnant women. However, they are not sufficiently sensitive for use in intermittent screening amongst 
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Background
Malaria during pregnancy is a preventable and treat-
able disease, which remains responsible for an enormous 
health, social and economic burden for communities in 
the developing world. Malaria infection is a major threat 
to maternal and neonatal survival, resulting in up to 
200,000 infant deaths and 10,000 maternal deaths each 
year [1]. Globally 125 million pregnancies remain at risk 
of malaria exposure [2], three quarters of which occur in 
the Asia–Pacific region.
Diagnosing malarial infection in pregnancy is challeng-
ing. In areas of high endemicity the majority of infected 
women are asymptomatic [3]. Diagnosis is further com-
plicated by low peripheral blood parasite densities and 
sequestration of Plasmodium falciparum-infected eryth-
rocytes in the placental intervillous space, termed pla-
cental malaria (PM) [4]. Antenatal detection of PM in 
particular is difficult [5], yet it is PM that is principally 
associated with a number of severe adverse pregnancy 
outcomes, including low birthweight (LBW) [4]. Inter-
mittent preventive treatment in pregnancy with sulfadox-
ine-pyrimethamine (SP-IPTp) provides regular parasite 
clearance and partial chemoprophylaxis in the absence 
of knowledge of infection status [6], overcoming some 
of the aforementioned diagnostic challenges. However, 
this intervention is threatened by drug resistance [7, 8], 
and may be inappropriate in low or unstable transmission 
settings [9], and as such, is currently not endorsed by the 
World Health Organization (WHO) for use outside of 
sub-Saharan Africa [6].
Recently, there has been considerable interest in inter-
mittent screening and treatment in pregnancy (ISTp) 
as an alternative to SP-IPTp, in particular in areas 
where high-level drug resistance is a concern [10]. This 
approach consists of regular antenatal screening events 
using rapid diagnostic tests (RDTs): they are accessible, 
affordable and require little operational expertise. Results 
of the first reported trial of ISTp, which was conducted 
in an area of moderately high malaria transmission in 
Ghana, suggest that ISTp using an lactate dehydrogenase-
based RDT prevents LBW and severe anaemia to a sim-
ilar extent to SP-IPTp [10], however the impact on PM 
was not assessed. Currently available RDTs are known 
to miss a substantial number of peripheral and placental 
infections [11]: as such, the findings of the Ghana trial 
indicate that infections undetectable by RDT may not be 
an important cause of maternal anaemia and LBW [10]. 
This contrasts findings of other research suggesting a role 
of ‘sub-RDT’ and ‘submicroscopic’ P. falciparum infec-
tions in causing adverse pregnancy outcomes, in par-
ticular anaemia, in some [5, 12–14], but not all [15, 16], 
studies evaluating these infections.
RDTs perform well outside of pregnancy and the WHO 
recommends their use for the diagnosis of malaria in 
this context [17]. Less is known about their accuracy in 
pregnancy, in particular when polymerase chain reaction 
(PCR) and placental histology are used as reference (‘gold 
standard’) [11]. Moreover, there is a paucity of informa-
tion regarding the utility of RDTs for the management 
and prevention of malaria in pregnancy in the Asia–
Pacific region, where both P. falciparum and P. vivax 
frequently co-exist [18–20] and cause poor pregnancy 
outcomes [21]. In Papua New Guinea (PNG), gestational 
malarial infection is common and frequently associated 
with adverse pregnancy outcomes [22, 23]. PNG national 
guidelines recommend RDTs and light microscopy (LM) 
to diagnose infection in symptomatic patients, including 
pregnant women [24]. Given all human malaria species, 
bar Plasmodium knowlesi, are sympatric in PNG, combi-
nation RDTs detecting both P. falciparum-histidine-rich-
protein-2 (HRP-2) and the genus-specific malaria antigen 
lactate dehydrogenase (pLDH) are most appropriate, 
and were shown to be appropriate for malaria treatment 
amongst febrile children in PNG [25]. To date, the perfor-
mance characteristics of these RDTs in pregnant women 
in PNG remain unknown.
This study evaluated the accuracy of an HRP2/pLDH 
combination RDT and LM to diagnose peripheral P. fal-
ciparum and P. vivax infections as detected by qPCR in 
the context of a large clinical trial of malaria prevention 
in pregnancy in PNG. Secondary objectives included an 
assessment of RDT performance characteristics relative 
to qPCR amongst both women with asymptomatic anae-
mia vs those with suspected malaria, and an evaluation of 
the performance of peripheral blood RDT, LM and qPCR 
to detect placental infection as observed on histological 
examination.
Methods
Study setting and design
This study was conducted between July 2010 and Novem-
ber 2013 in a prospective cohort of pregnant women 
enrolled in a clinical trial evaluating three doses of 
IPTp with SP plus azithromycin vs a single dose SP plus 
asymptomatic (anaemic) women. These findings have implications for the management of malaria in pregnancy. The 
adverse impact of infections undetected by RDT or LM on pregnancy outcomes needs further evaluation.
Keywords: Sensitivity, Specificity, Plasmodium, Pregnancy
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chloroquine and two placebo doses from second trimes-
ter in PNG (NCT01136850) [26]. The trial was conducted 
at nine health centres in Madang Province on the North 
Coast of PNG. The study area was previously considered 
hyperendemic for P. falciparum and P. vivax [27]. Preva-
lence of malaria in pregnancy fell considerably over the 
5 years prior to, and spanning, the study period [28].
During the original trial passive case detection forms 
(morbidity episodes) were completed for women who 
reported new or recent illness or where found to be 
anaemic. The trial was designed such that an RDT was 
performed during a morbidity episode when malaria 
was suspected clinically or when women were found to 
be moderately or severely anaemic (“anaemia”, defined 
here as a haemoglobin measurement (Hb) <90  g/L 
for moderate, and <60  g/L for severe (HemoCue Ltd, 
Angelholm, Sweden, accuracy of 1  g/L) and/or pres-
ence of pallor. Because women living in lowland PNG 
were highly likely to be at least mildly anaemic by 
WHO standards [29], a more conservative Hb cut-off 
for ‘anaemia’ was used to refine eligibility. Malaria was 
suspected if women had one or more of the following: 
fever (≥37.5 °C), history of fever (within previous 48 h), 
headache, chills and rigors, and joint or muscle pain. 
The choice of testing criteria for suspected malaria was 
based on previous research on symptoms associated 
with malaria in pregnancy in areas considered hyperen-
demic for P. falciparum [30, 31].
Accuracy of the RDT, and LM, to detect peripheral P. 
falciparum and P. vivax parasitaemia was assessed using 
qPCR as the Ref. [32]. A subset of trial participants had 
both an RDT and LM performed within 12 h of birth and 
placental histology assessed: this permitted an evaluation 
of the performance of peripheral blood RDT, LM and 
qPCR to detect active placental malaria.
Study participants
Pregnant women presenting for their first antenatal visit 
were screened according to inclusion criteria of the orig-
inal trial [26]. In brief, women were required to be <26 
gestational weeks by abdominal palpation, ≥16  years of 
age, without severe symptomatic anaemia (Hb <60 g/L), 
and without permanent disability or chronic medical 
conditions. HIV status of participants was not deter-
mined as antenatal HIV prevalence at the provincial hos-
pital (Modilon General Hospital) was 1.1 % (2009–2012, 
unpublished audit data). Trial participants who had one 
or more RDT done for aforementioned test criteria, and 
who had complete data for LM and qPCR for at least one 
RDT screening episode, were eligible for inclusion in the 
present study.
Sampling and laboratory procedures
Malaria was diagnosed using the commercially available 
three-band CareStart™ P.f/Pan combo RDT (Access Bio, 
USA, Lot MR1J3, Exp Feb 2014), which is pre-coated 
with two monoclonal antibodies, one detecting P. falci-
parum-specific malaria antigen HRP-2, the other genus-
specific LDH. Using LM as reference, the manufacturer 
reported sensitivities of 98 and 96 % to detect peripheral 
P. falciparum and P. vivax infections, respectively in non-
pregnant individuals [33].
Testing was undertaken by trained clinical research 
staff, and test kits were stored and performed accord-
ing to the manufacturer’s instructions [33]. There were 
no invalid test results. Women with positive RDTs were 
treated for malaria according to national guidelines (qui-
nine in first trimester, artemether-lumefantrine thereaf-
ter) [24].
Peripheral blood smears were prepared, and venous 
blood samples taken, each time an RDT was performed. 
Labeled blood smears were air-dried and stained with 
4 % Giemsa for 30 min. Thick smears were used to count 
the number of asexual parasites per 200 leukocytes (or 
per 500 if <10 parasites/200 leukocytes), assuming 8000 
leukocytes/µL of blood; slides were declared negative if 
no parasite was seen in 200 oil-immersion fields. Two 
microscopists read each slide, and third reads were per-
formed to resolve discrepant results [34]. If species dis-
crepancies were not resolved by this third read (5/1162 
RDT screening episodes), qPCR results were used and 
considered definite [32]. The microscopy laboratory at 
the PNG Institute of Medical Research undergoes regular 
and external quality control.
qPCR was performed to detect P. falciparum and P. 
vivax infections in peripheral and placental blood sam-
ples using an established methodology with a sensitiv-
ity of 1 parasite per microliter [35]. Plasmodium ovale 
and Plasmodium malariae infections in pregnant PNG 
women are rare [36], and budgetary constraints pre-
cluded their evaluation.
A subset of women had placental tissue collected for 
histological processing and analysis as described previ-
ously [37]. Placenta malaria was diagnosed and staged 
according to three histological features: presence of 
infected erythrocytes, malaria pigment in monocytes/
macrophages, and malaria pigment in fibrin deposits [38, 
39]. Active placental malaria was diagnosed upon detec-
tion of parasites.
Readers of all aforementioned the index tests (LM and 
RDT) and respective reference standards (qPCR, or pla-
cental histology) were blinded to the results of the other 
tests.
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Definitions
qPCR was used as the reference method for the detection 
of peripheral parasitaemia, and placental histology to 
identify women with active placental infection. All active 
placental infections were assumed to be due to P. falcipa-
rum: P. vivax has been associated with placental changes 
but these differ markedly from P. falciparum and are rare 
[40].
An RDT was classified positive for P. falciparum if 
showing (a) a positive reaction at the HRP-2 band, or (b) 
positive reactions at both the HRP-2 band and pLDH 
band. The RDT was classified positive for P. vivax if 
showing a positive reaction at the pLDH band only, or at 
both the HRP-2 band and pLDH band (possible mixed 
infection).
Statistical analysis
Data were double entered into a study databases (FoxPro 
9.0 or Excel, Microsoft, USA) and analysed using Stata 
12.0 (StataCorp, USA). Univariate comparisons of vari-
ables were undertaken using the Chi-squared and Fisher’s 
exact test for binary data, as appropriate, and the Stu-
dent’s t test and the Mann–Whitney-U test for paramet-
ric data and nonparametric data, respectively.
Sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) with 95  % confi-
dence intervals were calculated for the comparisons of 
RDT against qPCR, and LM against qPCR, for the detec-
tion of peripheral P. falciparum parasitaemia, and RDT, 
LM and qPCR of peripheral blood for the detection of 
active placental infection. Analysis of diagnostic perfor-
mance of RDT and LM to detect P. vivax infection was 
restricted to sensitivities, as qPCR did not include P. 
ovale and P. malariae. In addition, performance of RDT 
to detect malarial infection (any species) observed on LM 
(the current reference standard in PNG) was assessed. 
Sensitivities and specificities were compared using Lid-
dell’s exact test for pairwise comparisons of proportions 
[41, 42]. Parasite densities were presented as geometric 
means. All analyses used α < 0.05 as the cut-off for sta-
tistical significance. A sample size calculation was per-
formed for the original trial but not for the purpose of the 
present sub-analysis [26]. The study was reported accord-
ing to STARD guidelines (Standards for the reporting of 
diagnostic accuracy studies).
Ethical considerations
Written informed consent was obtained from all partici-
pating women. Study procedures were in accordance with 
good clinical and laboratory practice. Ethical approval for 
study protocol was obtained from the PNG Institute of 
Medical Research Institutional Review Board (0815), the 
PNG Medical Research Advisory Council (08.01), and 
the Melbourne Health Human Research Ethics Commit-
tee (2008.162). The trial was registered with the United 
States National Institutes of Health Clinical Trials Regis-
try (NCT01136850) and has been reported according to 
STARD guidelines.
Results
Of 2793 women enrolled in the original trial, 876 (31.4 %) 
women met the criteria for RDT testing at least once dur-
ing pregnancy, had complete data for peripheral blood 
RDT, LM and qPCR, and were thus eligible for inclu-
sion in the present analysis. The remaining 1917 were 
either withdrawn from the original study (n = 73, 2.6 %), 
did not meet testing criteria (n =  1322, 47.3 %), or had 
incomplete test results (n  =  522, 18.7  %; Fig.  1). Back-
ground characteristics of women who were tested solely 
for anaemia and those who had symptoms were similar 
(Table 1).
Amongst participating women (n = 876) a total of 1162 
tests were performed. One quarter of women (25.7  %, 
225) had two or more RDT screening episodes: the mean 
(median, range) number of days between testing episodes 
was 57 (42, 11–206) days. A quarter of tests were per-
formed because women presented with symptoms sug-
gestive of malaria (26.5 % of episodes, n = 308) (Table 1, 
Fig. 1). Four women had two positive RDT results (over 
60  days apart), despite receiving malaria treatment 
between positive tests. These women either had a nega-
tive RDT episode in between positive RDT episodes, or 
had infections caused by two different species (according 
to qPCR), making antigen persistence an unlikely reason 
for the positive second test.
qPCR detected peripheral infection during 190 (16.4 %) 
RDT screening episodes (165 P. falciparum, 19 P. vivax, 6 
P. falciparum/P. vivax mixed infections) (Table 1). 11.6 % 
(n = 135) RDT screening episodes were positive by RDT, 
including 114 for HRP-2. A total of 143 episodes (12.3 %) 
were positive by LM (133 P. falciparum, 10 P. vivax). 
Compared with women tested due to anaemia, women 
who presented with symptoms of suspected malaria were 
more likely to have a positive RDT and to have P. falcipa-
rum infection diagnosed by LM or qPCR, and had higher 
parasite densities when they were infected (Table 1).
Overall, RDT missed 54.4  % of peripheral P. falcipa-
rum detected by qPCR (93/171), and a higher proportion 
(81.4 %, 70/86) of infections were missed in women who 
were asymptomatic (Table 2). LM failed to detect a third 
of P. falciparum infections observed by qPCR, yet had 
higher sensitivity than RDT, particularly amongst asymp-
tomatic anaemic women (45.3  % [38.0, 53.4] vs 18.6  % 
[11.0-28.4], Liddell’s exact test, P  <  0.001) (Table  2). 
Both RDT and LM were highly specific, although LM 
had slightly better specificity for P. falciparum amongst 
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2,793 women enrolled into IPTp trial
1,162 screening episodes in 876 women (31.4%) with 
complete data for RDT, PCR and LM available for analysis
73 women excluded for trial reasons
1,322 women had no morbidity episodes
1,398 women (50.1%) with 2,075 morbidity episodes
Anaemia
(Haemoglobin < 90 g/L, and/or pallor)*
N = 854 (73.5% of episodes)
Suspected malaria (one or more):
- Fever (≥ 37.5 °C) 
- History of fever (within 48 hours)
- Headache
- Chills and rigors
- Joint and muscle pains
N = 308 (26.5% of episodes)
Testing criteria
* Includes 81 women tested for mild anaemia (Hb ≥ 90 and <110 g/L) or other reasons (e.g. dysuria) 
429 not fulfilling testing criteria/stock out
1,168 women (41.8%) with 1,646 test episodes
192 HRP2/aldolase RDT used
1,014 women (36.3%) with 1,454 test episodes
RDT performed >48 hours postpartum
1,011 women (36.2%) with 1,443 RDTs performed
Positive by RDT (any result)
n=158 
Negative by RDT (any result)
n=1,285 
PCR/LM result unavailable
n=23
PCR/LM result unavailable
n=258
PCR result available
N=135 
PCR result available
N=1,027
Positive
n=91
Negative
n=44
Positive
n=100
Negative
n=927
Fig. 1 Study flow diagram illustrating RDT test exclusion criteria, tests performed with matched PCR and LM availability, by testing criteria for 
anemia or suspected malaria
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symptomatic women compared to RDT (93.3 vs 89.2 %, 
Liddell’s exact test, P =  0.035) (Table  2). There were 22 
HRP-2 positive RDT screening episodes that were nega-
tive for P. falciparum by both LM and qPCR: qPCR 
threshold cycle and parasitaemia characteristics of dis-
crepant cases are presented in Additional file 1: Table S1. 
Diagnostic performance indicators of RDT and LM for 
the detection of P. falciparum by gravidity and trimester 
are presented in Additional file 2: Table S2.
Prevalence of peripheral P. vivax infection by qPCR was 
low (n = 25); although LM missed more than three quar-
ter of infections it detected twice as many compared to 
RDT (Table 2). Of 22 P. vivax infections missed by RDT 
nine were detected by LM (four of them were classified 
as P. falciparum by LM). The geometric mean density of 
these infections was 157 parasites/μL (median 125, range 
16–3341), with seven out of nine infections exhibiting a 
parasite density <200 parasites/μL. Specificities were not 
assessed as the RDT measured pan-specific LDH and 
qPCR for P. ovale and P. malariae were not performed.
A total of 49 of 143 (34.3  %) infections of any species 
detected by LM remained undetected by the HRP-2/pLDH 
RDT. Geometric mean density of these infections was 278 
parasites/μL (median 220, range 16–14,717; one infection 
gametocytes seen only). Specifically, RDT had a sensi-
tivity of 66.0 % (95 % CI 57.6–73.7), specificity of 96.1 % 
(94.7–97.2), PPV of 70.4 % (61.9, 77.9) and NPV of 95.2 % 
(93.7–96.4) to detect microscopic peripheral parasitaemia.
A quarter of women (221/876) had an RDT performed 
at delivery. Of these 71.5  % (n  =  158) had a placen-
tal biopsy taken for histological evaluation of placental 
malaria, and 31 (19.6  %) had evidence of active infec-
tion (Table  3). Most women had an RDT done because 
of asymptomatic anaemia (n  =  126, 79.8  %), and 13  % 
(n  =  21/158) were positive for P. falciparum by RDT. 
RDT on peripheral blood failed to detect more than half 
of the women with active placental infection, as did LM 
and qPCR (Table  3). Because most infections at deliv-
ery were asymptomatic, and sample size was small, the 
analysis was not further stratified by testing criteria. 
Table 1 Participant (n = 876) and episode (n = 1162) characteristics, by testing criteria
Descriptive data on participant pregnancy characteristics of all women tested and by those tested specifically for anaemia or symptomatic malaria criteria. Descriptive 
data of rapid diagnostic test results, light microscopy and qPCR by all women tested, and and by those tested specifically for anaemia or symptomatic malaria criteria. 
Numbers are mean ± standard deviation, median [range], geometric mean (median; range) or  % (n). SPAZ-IPTp, intermittent preventive treatment with sulfadoxine-
pyrimethamine plus azithromycin; HRP2, histidine-rich protein 2; pLDH, genus-specific lactate dehydrogenase
* Includes 81 women that were tested for mild anaemia (Hb ≥90 and <110 g/L) or for other reasons
** 6 women had mixed P. falciparum/P. vivax infections
Characteristic All (n = 876) Anaemia only* (n = 639) Symptomatic (n = 237) P
Participant
Age 24.6 ± 5.4 24.5 ± 5.4 24.8 ± 5.5 0.446
Primigravida 48.3 (423) 47.3 (302) 51.1 (121) 0.318
Fundal height at enrolment 22 [6–27] 22 [6–27] 21 [6–27] 0.002
Rural dweller 70.6 (618) 70.9 (453) 69.6 (165) 0.714
SPAZ‑IPTp 49.9 (437) 51.6 (330) 45.2 (107) 0.088
All (n = 1162) Anaemia only* (n = 854) Symptomatic (n = 308)
Episode
RDT
 HRP2 + 5.3 (62) 2.1 (18) 14.3 (44) <0.001
 HRP2 + pLDH + 4.5 (52) 1.2 (10) 13.6 (42) <0.001
 pLDH + 1.8 (21) 0.8 (7) 4.5 (14) <0.001
Light microscopy
 P. falciparum 11.5 (133) 5.6 (48) 27.6 (85) <0.001
 Asexual parasite density 5141 (1437; 16–123,484) 2237 (441; 39–19,372) 6731 (2418; 16–123,484) 0.001
 <200 parasites/µL 21.1 (28/133) 29.2 (14/48) 16.5 (14/85) 0.085
 P. vivax 0.9 (10) 0.9 (8) 0.7 (2) 0.480
 Asexual parasite density 434 (96; 16–3341) 470 (60; 16–3341) 288 (288; 143–432) <0.001
 <200 parasites/µL 80.0 (8/10) 87.5 (7/8) 50.0 (1/2) 0.378
qPCR positive
 P. falciparum** 14.7 (171) 10.1 (86) 27.6 (85) <0.001
 P. vivax** 2.2 (25) 2.5 (21) 1.3 (4) 0.358
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Symptomatic women were twice as likely to have active 
placental infection compared to those who were tested 
for anaemia alone (symptomatic 30.6 % [11/36]; anaemia 
only 16.4 % [20/122], P = 0.060).
Discussion
The performance characteristics and utility of an HRP-2/
pLDH combination RDT to detect parasitaemia in preg-
nant women in coastal PNG were evaluated as part of a 
clinical trial providing insecticide-treated bed nets and at 
least one dose of IPTp. RDTs were undertaken amongst 
trial participants presenting with anaemia or symptoms 
suggestive of malaria only. In this context RDT failed to 
diagnose about half of peripheral and placental P. fal-
ciparum infections detected by qPCR and histology, 
respectively. In addition, RDT missed one-third of infec-
tions (any species) detected by LM, falling well below the 
WHO performance criterion of 90 % sensitivity, consid-
ered to indicate adequate performance [17]. RDT perfor-
mance varied with screening criteria and malaria species: 
sensitivity to detect P. falciparum was higher amongst 
symptomatic women, and poorer for asymptomatic anae-
mic women, or in women infected with P. vivax. In line 
with previous findings [41], RDTs did not outperform 
LM to detect PCR-confirmed peripheral P. falciparum 
and P. vivax infections during pregnancy.
The overall poor performance of an HRP-2/pLDH 
combination RDT to detect P. falciparum as detected by 
qPCR suggests limited utility as a malaria screening tool 
in pregnancy in PNG. Poor performance observed in 
this study may be explained by low sensitivity to detect 
low density parasitaemias, although the median parasite 
densities for P. falciparum exceeded the minimum detec-
tion threshold documented in laboratory testing of the 
RDT test (>100/µL) [44] and those specified by the WHO 
(>200/µL) in all groups [45]. Not all previous studies 
evaluating HRP-2-based RDTs demonstrated inferiority 
of peripheral blood RDT compared to LM. In asymp-
tomatic pregnant Congolese women RDT was better at 
diagnosing peripheral infection detected by nested PCR 
compared to LM [43]. In Uganda, peripheral blood HRP-
2-RDT and LM detected most placental infections (his-
tology), and performed best when combined [41]. The 
differences in findings may be explained by differences in 
parasite densities, HRP-2-RDT brand, as well as labora-
tory procedures and assays used.
It is well established that in areas with moderate-to-
high transmission intensity the majority of parasitaemic 
pregnant women will be asymptomatic. As such, RDT 
performance to detect infection in asymptomatic women 
is critical. RDTs had poor sensitivity for detection of 
peripheral P. falciparum parasitaemia amongst asymp-
tomatic women with anaemia (Hb <90 g/L). This finding 
has implications at a number of levels.
The suboptimal performance of the HRP-2/pLDH RDT 
amongst asymptomatic anaemic women suggests that 
Table 2 Comparison of  HRP2/pLDH RDT (and light microscopy) against  qPCR (reference) for  detection of  P. falciparum 
and P. vivax infection in peripheral blood (n = 1162)
Performance characteristics of RDT against qPCR for detection of infection by species in peripheral blood samples. RDT rapid diagnostic test, LM light microscopy, 
qPCR real-time polymerase chain reaction, PPV positive predictive value, NPV negative predictive value. Sensitivity was defined as the proportion of true positives (RDT 
or LM positive) from all matched positive qPCR samples while specificity was defined as the proportion of true negatives (RDT or LM negative results) of all matched 
qPCR negative samples. Positive predictive value was defined as how frequently the RDT or LM tested positive in matched qPCR positive samples, while negative 
predictive value was defined as the frequency of RDT or LM testing negative in matched qPCR negative samples
* Liddell’s exact test P < 0.05
** Liddell’s exact test P < 0.001
Category/test Prevalence by qPCR 
(95 % CI)
Sensitivity (95 % CI) Specificity (95 % CI) PPV (95 % CI) NPV (95 % CI) Infections missed (per 
1000 women)
P. falciparum
 Overall
  RDT 14.7 (12.7, 16.9) 45.6 (38.0, 53.4)** 96.4 (95.0, 97.4) 68.4 (59.1, 76.8) 91.1 (89.2, 92.8) 93 of 171 (54.4 %)
  LM 63.7 (56.1, 70.9)** 97.6 (96.4, 98.4) 82.0 (74.4, 88.1) 94.0 (92.3, 95.4) 62 of 171 (36.3 %)
 Anaemia only (n = 854)
  RDT 10.1 (8.1, 12.3) 18.6 (11.0, 28.4)** 98.4 (97.3, 99.2) 57.1 (37.2, 75.5) 91.5 (89.4, 93.3) 70 of 86 (81.4 %)
  LM 45.3 (34.6, 56.5)** 98.8 (97.8, 99.5) 81.3 (67.4, 91.1) 94.2 (92.3, 95.7) 47 of 86 (54.7 %)
 Symptomatic (n = 308)
  RDT 27.6 (22.6, 32.6) 72.9 (62.2, 82.0) 89.2 (84.4, 93.0)* 72.1 (61.4, 81.2) 89.6 (84.9, 93.3) 23 of 85 (27.1 %)
  LM 82.4 (72.6, 89.8) 93.3 (89.1, 96.2)* 82.4 (72.6, 89.8) 93.3 (89.1, 96.2) 15 of 85 (17.6 %)
P. vivax
 RDT 2.2 (1.3, 3.2) 12.0 (2.6, 31.5) – – – 22 of 25 (88.0 %)
 LM 24.0 (9.4, 45.1) – – – 19 of 25 (76.0 %)
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it may not be appropriate to use this diagnostic tool as 
a component of IST. Although the association between 
infections missed by RDT and adverse mother-infant 
outcomes could not be evaluated in the present study, a 
recent study conducted in Benin provides compelling 
evidence of the detrimental effect of submicroscopic 
infections on increased risk of maternal anaemia and 
low birth weight in primigravidae [14]. Second, malarial 
infection is a well-established risk factor for gestational 
anaemia [1], and preliminary data from the parent trial 
indicates the same [46]. This means that the testing crite-
ria of anaemia should bias towards parasitaemia. Future 
studies in unselected women, including those without 
symptoms and a normal Hb, would be expected to show 
similar, or even poorer sensitivity of RDTs for detection 
of parasitaemia. Third, anaemia is common in pregnant 
and non-pregnant individuals in PNG [29], yet in the pre-
sent study the proportion of anaemic women with parasi-
taemia was comparatively low. This means anaemia is not 
a valuable clinical criteria to improve RDT performance, 
and calls for further research into the causes of anaemia 
in pregnant women in PNG.
Taken together these findings suggest that further opti-
mization of existing RDTs, or the development of novel, 
molecular approaches such as loop-mediated isothermal 
amplification (LAMP) [47, 48], to accurately screen for 
infection in antenatal clinics in malaria-endemic areas 
is urgently required. Until this is achieved, and more is 
known about the association between subpatent infec-
tion and adverse pregnancy outcomes in the region, this 
study supports the current IPTp policy in coastal PNG of 
three doses of SP, rather than ISTp.
RDT performance was better in women screened 
because of malaria symptoms than for asymptomatic 
anaemia, possibly because of the higher parasite densities 
in symptomatic women. This observation is in keeping 
with previous research that demonstrates near-adequate 
performance in febrile pregnant women in Africa [41]. 
The present testing criteria were based on malaria symp-
toms described in hyperendemic areas in Africa [30, 31]. 
Further optimization of testing criteria specific for PNG 
may improve RDT performance, however complex clinical 
algorithms to guide RDT testing may be impractical in a 
resource-limited setting like PNG. In addition, the preva-
lence of malaria in pregnant women was lower than previ-
ously observed [28, 36], probably because of the intensified 
malaria control strategies during the study period [49, 50]. 
If changes in malaria prevalence and immunity to malaria 
in pregnancy continue in the region [28], an increased 
number of symptomatic infections are anticipated, and on-
going studies of the usefulness of RDTs to identify malaria 
in pregnancy will be required. The majority of women with 
symptoms did not appear to have malaria; the underlying 
causes of their symptoms are unknown.
At delivery, all measures of parasitaemia in periph-
eral blood significantly underestimated active placental 
malaria by histology, probably due to occult placental 
sequestration. This supports a previous study by Mayor 
et al. [5], who show that HRP-2-based RDTs fail to detect 
the majority of placental infections confirmed by qPCR. 
Table 3 RDT, LM and  qPCR of  peripheral blood and  detection active P. falciparum placental infection on  histology 
(n = 158)
Performance characteristics of RDT and LM for detection of active placental malaria on placental histology. RDT rapid diagnostic test, LM light microscopy, qPCR real-
time polymerase chain reaction, PPV positive predictive value, NPV negative predictive value. Sensitivities and specificities of RDT, LM and qPCR were not statistically 
different (all P > 0.05, Liddell’s exact test)
Placental infection (histology) Sensitivity (%) 
(95 % CI)
Specificity (%) 
(95 % CI)
PPV (%) (95 % CI) NPV (%) (95 % 
CI)
Positive (n = 31) Negative (n = 127)
RDT
 Positive (n = 21) 14 7 45.2 (27.3, 64.0) 94.5 (89.0, 97.8) 66.7 (43.0, 85.4) 87.6 (80.9, 92.6)
 Negative (n = 137) 17 117
LM
 Positive (n = 16) 14 2 45.2 (27.3, 64.0) 98.4 (94.4, 99.8) 87.5 (61.7, 98.4) 88.0 (81.5, 92.9)
 Negative (n = 142) 17 125
qPCR
 Positive (n = 15) 13 2 41.9 (24.5, 60.9) 98.4 (94.4, 99.8) 86.7 (59.5, 98.3) 87.4 (80.8, 92.4)
 Negative (n = 143) 18 125
LM + RDT
 Positive (n = 25) 17 8 54.8 (36.0, 72.7) 93.7 (88.0, 97.2) 68.0 (46.5, 85.1) 89.5 (83.0, 94.1)
 Negative (n = 133) 14 119
Page 9 of 11Umbers et al. Malar J  (2015) 14:412 
Here, qPCR of placental blood detected more infec-
tions than histology, and was used hence as the refer-
ence standard: performance of the HRP-2/RDT against 
placental blood PCR was not evaluated in this cohort. In 
the Congo HRP-2 RDT were useful for the detection of 
placental infection (according to histology) when used 
in combination and in presence of fever [41], however 
the combination of RDT and LM results did not further 
enhance performance during pregnancy in this study 
(Table 3), and the small sample size of delivery episodes 
precludes a meaningful sub-analysis by test criteria. 
Unlike African-based reports [11], the present study sug-
gests there is insufficient evidence to support the use of 
RDTs for the diagnosis of placental malaria in PNG.
The few studies to evaluate RDT for P. vivax infection 
in non-pregnant individuals report varying performance 
[19, 20, 44]. The prevalence of P. vivax infections was 
lower than expected, and it was a rare cause of clinical 
malaria in the present study. The limited data show that 
RDT or LM missed nearly three quarters of infections 
detected by PCR. This suggests it is not a good screen-
ing tool for P. vivax infection in pregnancy. Future studies 
including PCR data to differentiate potential P. ovale and 
P. malariae infections, which are present but rare [36, 
51], are required for a more definite and comprehensive 
RDT performance analysis for the detection of P. vivax 
infection.
Although this study is one the largest to assess the 
usefulness of an HRP-2/pLDH RDT in pregnancy in 
the Asia–Pacific region, it is subject to a number of 
limitations. First, the findings are restricted to pregnant 
women presenting with moderate to severe anaemia and/
or non-specific clinical malaria symptoms: RDT perfor-
mance amongst asymptomatic pregnant women without 
anaemia is unknown. Second, only a subset of women 
were tested at delivery and had placental biopsies taken: 
the small sample size increases the risk of random error 
and does not allow definitive conclusions regarding the 
performance of HRP-2/pLDH-RDT to detect placental 
infection. In addition, histology was not evaluated against 
placental blood qPCR. Third, the low prevalence of infec-
tion overall limits extrapolation of findings to areas of 
higher malaria transmission, but does reflect much of 
the malaria epidemiology across the Asia–Pacific region. 
Fourth, this study was conducted within the context 
of an IPTp trial in women sleeping under insecticide 
treated bet nets. Although most RDT screening events 
took place at enrolment, before women received any 
treatment, interpretation of the study data is limited to 
this context. Moreover, qPCR species-correction of five 
infection episodes may have biased the diagnostic perfor-
mance of LM. While operator error cannot be excluded 
at clinical or laboratory level, clinical training, refresher 
training and competency assessment were provided 
throughout the study, rendering operator factors as an 
unlikely cause of poor RDT performance. Microscopy 
and molecular diagnostic facilities at the PNG Institute of 
Medical Research undergo regular external quality con-
trol and operate at the highest standard. Finally, the low 
prevalence of malaria in this cohort and the study design 
did not permit an evaluation of the impact of missed 
infections on pregnancy outcomes.
Conclusion
At the current level of transmission in lowland coastal 
PNG, HRP-2/pLDH RDTs may be used to diagnose 
peripheral P. falciparum infections in symptomatic preg-
nant women, but should not be employed for screen-
ing amongst asymptomatic (anaemic) women. A more 
sensitive tool is required to effectively detect and guide 
treatment of all women with Plasmodium spp infections. 
The potential adverse impact of infections undetected by 
RDT or LM on pregnancy outcomes needs further evalu-
ation. Until more sensitive point of care diagnostics are 
available, IPTp with SP is likely to remain the optimal 
strategy for malaria prevention in pregnancy in PNG.
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